Effect of toremifene and ospemifene, compared to acolbifene, on estrogen-sensitive parameters in rat and human uterine tissues

Hormone Molecular Biology and Clinical Investigation

Volumn 1, Issue 3, 2010, Pages 139-146

  Fernand, Labrie ^a,b   Martel, Céline ^a   Gauthier, Sylvain ^a   Pelletier, Georges ^a   Sancéau, Jean Yves ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

acolbifene; Ishikawa cells; ospemifene; rat uterus; toremifene

Indexed keywords

ACOLBIFENE; ALKALINE PHOSPHATASE; ESTRADIOL; ESTROGEN; OSPEMIFENE; TOREMIFENE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIAL THICKNESS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC50; NONHUMAN; PRIORITY JOURNAL; RAT; STROMA CELL; UTERUS WEIGHT;

EID: 84987844143     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.016     Document Type: Article

References (38)

1. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 2003;46:883-908.
2. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 2003;46:1081-111.
3. Labrie F., Labrie C., Belanger A., Giguère V., Simard J., Mérand Y., Gauthier S., Luu-The V., Candas B., Martel C., Luo S. Pure selective estrogen receptor modulators., new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. In: Scolnick EM., editor. Advances in protein chemistry: drug discovery and design. San Diego., CA: Academic Press., 2001:293-368.
4. Fisher B., Costantino JP., Lawrence Wickerham D., Redmond CK., Kavanah M., Cronin WM., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
5. Plouffe L. Jr. Selective estrogen receptor modulators (SERMs) in clinical practice. J Soc Gynecol Investig 2000;7(Suppl 1): S38-S46.
6. Coe PL., Scriven CE. Crossed coupling of functionalised ketones by low valent titanium (the McMurry reaction): a new stereo-selective synthesis of tamoxifen. J Chem Soc Perkin Trans 1986;1:475.
7. Nagashima T., Davies HM. Catalytic asymmetric solid-phase cyclopropanation. J Am Chem Soc 2001;123:2695-6.
8. Gauthier S., Mailhot J., Labrie F. New highly stereoselective synthesis of (Z)-4-hydroxytamoxifen and (Z)-4-hydroxytoremifene via McMurry reaction. J Org Chem 1996;61:3890-3.
9. Gauthier S., Caron B., Cloutier J., Dory YL., Favre A., Larouche D., Mailhot J., Ouellet C., Schwerdtfeger A., Leblanc G., Martel C., Simard J., Mérand Y., Bélanger A., Labrie C., Labrie F. (S)-( + )-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-pipeiidinyl)-ethoxy] phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent., specific., and orally active nonsteroidal antiestrogen. J Med Chem 1997;40:2117-2122.
10. Simard J., Sanchez R., Poirier D., Gauthier S., Singh SM., Merand Y., Bélanger A., Labrie C., Labrie F. Blockade of the stimulatory effect of estrogens., OH-tamoxifen., OH-toremifene., droloxifene and raloxifene on alkaline phosphatase activity by the antiestro-gen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res 1997;57:3494-7.
11. Littlefield BA., Gurpide E., Markiewicz L., McKinley B., Hoch-berg RB. A simple and sensitive microtiter plate estrogen bio-assay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of Δ5 adrenal steroids. Endocrinology 1990;127:2757-62.
12. Rodbard D. Apparent positive cooperative effect in cyclic AMP and corticosterone production by isolated adrenal cells in response to ACTH analogues. Endocrinology 1974;94:1427-37.
13. Kramer CY. Extension of multiple range tests to group means with unique numbers of replications. Biometrics 1956;12: 307-10.
14. Labrie F., Labrie C., Belanger A., Simard J., Giguere V., Tremblay A., Tremblay G. EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol 2001;79:213-25.
15. Labrie F., Labrie C., Bélanger A., Simard J., Gauthier S., Luu-The V., Merand Y., Giguère V., Candas B., Luo S., Martel C., Singh SM., Fournier M., Coquet A., Richard V., Charbonneau R., Char-penet G., Tremblay A., Tremblay G., Cusan L., Veilleux R. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 1999;69:51-84.
16. Qu Q., Zheng H., Dahllund J., Laine A., Cockcroft N., Peng Z., Koskinen M., Hemminki K., Kangas L., Vaananen K., Harkonen P. Selective estrogenic effects of a novel triphenylethylene compound., FC1271a., on bone., cholesterol level., and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000; 141:809-20.
17. Gennari L., Merlotti D., Valleggi F., Nuti R. Ospemifene use in postmenopausal women. Expert Opin Investig Drugs 2009;18: 839-49.
18. Komi J., Lankinen KS., Harkonen P., DeGregorio MW., Voipio S., Kivinen S., Tuimala R., Vihtamaki T., Vihko K., Ylikorkala O., Erkkola R. Effects of ospemifene and raloxifene on hormonal status., lipids., genital tract., and tolerability in postmenopausal women. Menopause 2005;12:202-9.
19. Gutman M., Couillard S., Roy J., Labrie F., Candas B., Labrie C. Comparison of the effects of EM-652 (SCH 57068), Tamoxifen., toremifene., droloxifene., idoxifene., GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer 2002;99:273-8.
20. Bryant HU., Wilson PK., Adrian MD., Cole HW., Phillips DL., Dodge JA., Grese TA., Sulka JP., Glasebrook AL. Selective estrogen receptor modulators: pharmocological profile in the rat uterus. J Soc Gynecol Invest 1996;3(Suppl):152A.
21. Sato M., Rippy MK., Bryant HU. Raloxifene., tamoxifen., nafoxi-dine., or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-12.
22. Ashby J., Odum J., Foster JR. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul Toxicol Pharmacol 1997;25:226-31.
23. Martel C., Picard S., Richard V., Beelanger A., Labrie C., Labrie F. Prevention of bone loss by EM-800 and raloxifene in the ova-riectomized rat. J Steroid Biochem Mol Biol 2000;74:45-56.
24. Vogel VG., Costantino JP., Wickerham DL., Cronin WM., Cec-chini RS., Atkins JN., Bevers TB., Fehrenbacher L., Pajon ER Jr., Wade JL III., Robidoux A., Margolese RG., James J., Lippman SM., Runowicz CD., Ganz PA., Reis SE., McCaskill-Stevens W., Ford LG., Jordan VC., Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. J Am Med Assoc 2006;295: 2727-41.
25. Rutanen EM., Heikkinen J., Halonen K., Komi J., Lammintausta R., Ylikorkala O. Effects of ospemifene., a novel SERM., on hormones., genital tract., climacteric symptoms., and quality of life in postmenopausal women: a double-blind., randomized trial. Menopause 2003;10:433-9.
26. Fisher B., Dignam J., Bryant J., DeCillis A., Wickerham DL., Wol-mark N., Costantino J., Redmond C., Fisher ER., Bowman DM., Deschenes L., Dimitrov NV., Margolese RG., Robidoux A., Shi-bata H., Terz J., Paterson AHG., Feldman MI., Farrar W., Evans J., Lickley HL. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-positive tumors. J Natl Cancer Instit 1996;88: 1529-42.
27. Chalbos D., Philips A., Galtier F., Rochefort H. Synthetic anti-estrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-mono-phosphate in MCF7 cells. Endocrinology 1993;133:571-6.
28. Gottardis MM., Robinson SP., Satyaswaroop PG., Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48:812-5.
29. Howell A., Dodwell DJ., Laidlaw I., Anderson H., Anderson E. Tamoxifen as an agonist for metastatic breast cancer. In: Gold-hirsch A., editor. Endocrine therapy of breast cancer IV. Berlin: Springer-Verlag., 1990:49-58.
30. Poulin R., Simard J., Labrie C., Petitclerc L., Dumont M., Lagace L., Labrie F. Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. Endocrinology 1989;125:392-9.
31. Wakeling AE. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J Steroid Biochem 1989;34:183-8.
32. Kedar RP., Bourne TH., Powles TJ., Collins WP., Ashley SE., Cos-grove DO., Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-21.
33. Robinson DC., Bloss JD., Schiano MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol 1995;59:186-90.
34. Marttunen MB., Cacciatore B., Hietanen P., Pyrhonen S., Tiitinen A., Wahlstrom T., Ylikorkala O. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2001;84:897-902.
35. Fornander T., Rutquist LE., Cedermark B., Glas U., Mattsson A., Silfversward C., Skoog L., Somell A., Theve T., Wilking N., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-20.
36. Magriples U., Naftolin F., Schwartz PE., Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
37. Gusberg SB. Tamoxifen for breast cancer: associated endometrial cancer. Cancer 1990;65:1463-4.
38. Berger L., El-Alfy M., Martel C., Labrie F. Effects of dehydro-epiandrosterone., Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol 2005;96:201-15.